全球细胞及基因治疗市场成长机会及预测（至2030年）

摘要：细胞和基因治疗市场

全球细胞和基因治疗市场预计在2024年达到99.8亿美元，预计到2030年将达到513.7亿美元，2025年至2030年的复合年增长率为31.4%。临床转化方面的快速进展、基因修饰细胞疗法的核准数量不断增加以及体内基因治疗的日益普及，正在推动整个细胞和基因治疗（CGT）市场的持续增长。

关键市场趋势与洞察

• 北美预计在 2024 年占据全球细胞和基因治疗市场最大的收入份额，这得益于加快的监管流程、强大的创业融资以及早期采用基于结果的报销模式。
• 在美国，随着 CAR-T 疗法、基因编辑疗法和体内基因疗法的核准不断增加，肿瘤学和罕见遗传疾病领域的商业化进程正在加速。
• 按治疗类型划分，基因修饰细胞疗法将在 2024 年占据主导地位，这反映出其在骨髓恶性肿瘤中的高普及率以及二线治疗核准的不断扩大。
• 在基因治疗市场，病毒载体、脂质奈米颗粒和基因组编辑技术的进步推动了生物递送平台的快速发展。
• 亚太地区正在崛起成为成长最快的地区，这得益于日本和中国不断加快的法规结构建设以及国内製造业投资的增加。

製造自动化、智慧工厂和数位化品质系统的快速发展进一步增强了细胞和基因治疗市场的扩充性。随着监管政策的日益明朗和报销模式的日益成熟，预计到预测期结束时，细胞和基因治疗（CGT）市场将从利基创新转变为主流治疗支柱。

成长驱动因素：细胞和基因治疗市场

细胞和基因治疗市场受到多种结构性成长因素的驱动，这些因素正在塑造其发展进程。

首先，基因组编辑工具、病毒载体和递送平台的快速创新正在加速临床成功率的提升。这些进步正将基因治疗市场从治疗罕见疾病扩展到治疗更常见的疾病。

其次，诸如RMAT、PRIME和有条件核准等监管加速机制显着缩短了研发週期。这种监管支持正在提高CGT治疗市场的资本效率和投资报酬率。

第三，透过自动化和数数位化的製造流程转型正在克服传统的扩充性限制。智慧工厂和人工智慧驱动的製程控制正在降低变异性，并实现细胞和基因治疗市场中稳定的商业化生产。

第四，不断发展的报销模式，包括按效果付费合约和分期付款，正在缓解支付方对高额前期费用的抵触情绪。这些框架正在扩大细胞和基因治疗（CGT）市场的准入范围，并稳定长期需求。

最后，创业融资和策略联盟的增加正在推动产品线扩张和生态系统成熟，从而增强 CGT 治疗市场持续成长的势头。

成长抑制因素：细胞和基因治疗市场

儘管细胞和基因治疗市场成长势头强劲，但该市场仍面临一些限制因素，这些因素正在限制细胞和基因治疗（CGT）市场的近期成长。

高昂的治疗费用仍然是主要挑战，尤其是对于一次性根治性治疗而言。儘管报销模式不断演变，但由于经济承受能力的担忧，成本效益高的医疗保健系统仍然难以全面采用这些模式。

製造复杂性和产能限制仍然存在：虽然自动化提高了扩充性，但技术转移风险、人才短缺和品管挑战仍然影响着 CGT 治疗市场。

本报告分析了全球细胞和基因治疗市场，提供了六年收入预测（2025-2030 年）和全面的市场评估，包括研发管线发展、技术趋势、监管和报销模式、策略合作伙伴关係以及新兴的上市策略。

目录

调查范围

• 市场定义、范围和细分
• 分割
• 定义

成长环境：CGT治疗市场的转型

• 为什么经济成长变得越来越困难？
• 战略必要性
• 三大战略要务对CGT治疗产业的影响

CGT治疗市场生态系统

• 主要亮点
• 管道简介
• 产品线概览：细胞疗法
• 研发管线概览：基因疗法和基因工程细胞疗法
• 研发管线概览：基因工程细胞疗法
• 临床试验的挑战与因应策略
• 製造挑战及因应策略
• CGT连续体中的技术趋势
• 策略伙伴关係与联盟
• 北美：资本利得税法规和赎回模式
• 欧洲：资本利得税监理与赎回模式
• 亚太地区：资本利得税法规与赎回模式
• 拉丁美洲和中东：资本利得税法规和赎回模式
• 併购评估
• 创投评估
• 竞争环境
• 主要竞争对手

CGT治疗市场成长要素

• 成长指标
• 成长驱动因素
• 成长抑制因素
• 研究过程和方法
• 预测考量
• 收入预测
• 收入预测分析
• 按产品分類的收入预测
• 收入预测分析
• 按治疗领域分類的收入预测
• 收入预测分析
• 按地区分類的收入预测
• 预测分析：按地区
• 收益分成
• 收入份额分析

成长要素：细胞疗法

• 成长指标
• 收入预测
• 按来源分類的收入预测
• 预测分析

成长要素：基因改造细胞疗法

• 成长指标
• 收入预测
• 按技术分類的收入预测
• 预测分析

成长要素：基因治疗

• 成长指标
• 收入预测
• 按技术分類的收入预测
• 预测分析

发展机会

• 成长机会 1：加速核准的监理咨询服务
• 成长机会2：利用人工智慧优化生物工艺
• 成长机会3：建构一体化载体与质体生产中心
• 成长机会 4：利用区块链和物联网实现低温运输和第三方物流网路现代化
• 简称
• 成长机会带来的益处和影响
• 下一步
• 图表清单
• 免责声明

Platform Innovation, Regulatory Maturity, and Global Capacity Expansion Are Catalyzing the Next Wave of Growth in Cell and Gene Therapy

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms-including in vivo CRISPR gene editing, allogeneic "off-the-shelf" cell therapies, and automated smart-factory bioprocessing-the market is projected to cross $50 billion by 2030 and reflect a greater than 30% CAGR between 2024 and 2030. This growth aligns with the expanding global disease burden: oncology indications continue to dominate CGT development, while rare genetic, neurological, hematologic, and ophthalmologic disorders fuel diversification into new high-value segments.

Pipeline momentum is unprecedented. In 2025, oncology remains the largest therapeutic focus, with hematologic malignancies accounting for the majority of trials and solid-tumor programs accelerating through improved tumor-microenvironment targeting and next-generation vectors. Rare diseases continue to anchor the CGT landscape-over two-thirds of rare-disease trials target rare cancers, while new programs are broadening into genetically linked common diseases such as Alzheimer's, cardiovascular disease, arthritis, and HIV. Approvals of CASGEVY™, Lyfgenia™, Elevidys™, Ryoncil™, Hemgenix(R), Roctavian(R), Vyjuvek(R), and emerging CNS and ophthalmology therapies demonstrate durable evidence that ex vivo and in vivo modalities offer curative potential across multiple disease categories.

Major scientific and operational inflection points are reshaping the sector. In vivo gene editing is rapidly progressing-Intellia's NTLA-2002 entered Phase III, Interius initiated the first in vivo CAR-T clinical pathway, and YolTech advanced LNP-delivered gene-editing into human studies. Parallel advances in automated manufacturing (e.g., Cellares Cell Shuttle™ receiving FDA AMT designation) and the rise of regional "IDMO Smart Factories" in the United States, Europe, and Japan signal a decisive move toward scalable, closed system, digitally orchestrated CGT production. Manufacturing readiness (MRL), AMT-qualified platforms, and cloud-enabled QA are becoming as important as clinical data for asset valuation.

Globally, the regulatory landscape is evolving in support of innovation.

North America leads with outcomes-based reimbursement models (CMS CGT Access Model with more than 33 states on board), accelerated approvals, and growing manufacturing capacity.

Europe advances through managed entry agreements and national value-based reimbursement, while APAC remains the fastest-growing geography, driven by Japan's expedited pathways, China's maturing NMPA frameworks, and South Korea's Rare Disease Act.

LATAM and the Middle East show early regulatory traction, led by the UAE and Saudi Arabia, though broad access remains limited.

Investment and M&A activity reflect a strategic focus on scalable platforms and next-generation delivery. The sector has shifted from megadeals to mid-sized "string-of-pearls" acquisitions-exemplified by Roche-Poseida, AbbVie-Capstan, Lilly-Verve, and Gilead-Interius-focused on in vivo editing, allogeneic CAR-T, and improved vector technologies. While venture investments have cooled relative to 2021 peaks, capital remains available for differentiated AAV capsids, LNPs, base/prime-editing technologies, and automated manufacturing platforms.

This research service provides a 6-year revenue forecast (2025 to 2030) and a comprehensive market evaluation across North America, Europe, APAC, MENASA, and Latin America, covering pipeline evolution, technology trends, regulatory and reimbursement models, strategic partnerships, and emerging GTM strategies. The analysis spans in vivo gene therapy, ex vivo gene therapy, gene-modified cell therapy, non-genetically modified cell therapy, and hybrid ex/in vivo modalities, each experiencing high double-digit growth. It identifies next-generation areas-such as allogeneic iPSC-derived therapies, base-editing, smart-factory automation, and in vivo CAR-T-as future growth engines.

Overall, the CGT therapeutics market is entering a period of accelerated commercialization, underpinned by robust late-stage pipelines, regulatory innovation, outcomes-based reimbursement, and transformative manufacturing technologies. Stakeholders that invest early in automated platforms, vector innovation, real-world evidence frameworks, and integrated global access strategies will be best positioned to capture growth in this rapidly expanding, high-impact therapeutic domain.

Report Summary: Cell And Gene Therapy Market

The global Cell & Gene Therapy Market size was estimated at USD 9.98 billion in 2024 and is projected to reach USD 51.37 billion by 2030, growing at a CAGR of 31.4% from 2025 to 2030. Rapid clinical translation, increasing approvals of gene-modified cell therapies, and expanding adoption of in vivo gene therapies are driving sustained growth across the cell and gene therapy (CGT) market.

Key Market Trends & Insights

• North America accounted for the largest revenue share of the global Cell And Gene Therapy Market in 2024, supported by accelerated regulatory pathways, strong venture funding, and early adoption of outcomes-based reimbursement models.
• In the United States, increasing approvals of CAR-T, gene-editing, and in vivo gene therapies are accelerating commercialization across oncology and rare genetic disorders.
• By therapy type, gene-modified cell therapies held the dominant position in 2024, reflecting strong uptake in hematologic malignancies and expanding second-line treatment approvals.
• The Gene therapy market is witnessing rapid momentum in vivo delivery platforms, driven by advancements in viral vectors, lipid nanoparticles, and genome-editing technologies.
• Asia Pacific is emerging as the fastest-growing region, supported by accelerated regulatory frameworks in Japan and China and increasing domestic manufacturing investments.

Market Size & Forecast

• 2024 Market Size: USD 9.98 Billion
• 2030 Projected Market Size: USD 51.37 Billion
• CAGR (2025-2030): 31.4%
• North America: Largest Market in 2024
• Asia Pacific: Fastest-Growing Market

The rapid evolution of manufacturing automation, smart factories, and digital quality systems is further strengthening the scalability of the CGT therapeutics market. As regulatory clarity improves and reimbursement models mature, the cell and gene therapy (CGT) market is expected to transition from niche innovation to a mainstream therapeutic pillar by the end of the forecast period.

Market Overview & Trends: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is transitioning from experimental innovation to an integrated therapeutic ecosystem built on platform scalability, regulatory convergence, and commercial readiness. Historically constrained by high costs, manufacturing complexity, and reimbursement uncertainty, the cell and gene therapy (CGT) market is now benefiting from structural shifts that support broader adoption.

One of the most significant trends shaping the CGT therapeutics market is the shift from autologous, batch-based manufacturing toward automated, closed-system platforms. Smart factories, digital batch records, and AI-driven process analytics are reducing production timelines, improving consistency, and lowering cost of goods. These advancements are enabling developers to move beyond ultra-rare indications and address larger patient populations.

Another defining trend in the Gene therapy market is the rapid growth of in vivo delivery platforms, including AAV and lipid nanoparticle-based systems. These approaches reduce logistical complexity and expand treatment accessibility compared to ex vivo therapies. Concurrently, hybrid models combining cell and gene engineering are emerging as next-generation innovation zones within the Cell And Gene Therapy Market.

Regulatory frameworks are also evolving. Agencies such as the FDA, EMA, and PMDA are refining guidance on comparability, long-term follow-up, and accelerated approvals. Programs such as RMAT, PRIME, and Sakigake are compressing development timelines by 12-18 months, improving capital efficiency across the cell and gene therapy (CGT) market.

On the commercial front, reimbursement models are shifting toward outcomes-based agreements and annuity-style payments. These mechanisms are addressing payer concerns around high upfront costs while enabling sustainable access. Collectively, these trends are redefining the operating model of the CGT therapeutics market, positioning it for sustained long-term growth.

Scope of Analysis: Cell and Gene Therapy Market

This analysis examines the global Cell And Gene Therapy Market with a comprehensive assessment of industry structure, technology evolution, and commercial dynamics. The study period spans 2021-2030, with 2024 as the base year and 2025-2030 as the forecast period. All market values are expressed in US dollars.

The scope covers therapeutic modalities within the cell and gene therapy (CGT) market, including non-genetically modified cell therapies, gene-modified cell therapies, and gene therapies. DNA- and RNA-based therapeutics outside regenerative medicine frameworks are excluded. The CGT therapeutics market assessment includes approved products and advanced pipeline assets expected to reach commercialization during the forecast horizon.

Geographic coverage includes North America, Europe, Asia-Pacific, Latin America, and the Middle East, reflecting both mature and emerging adoption cycles in the Gene therapy market. Regional analysis focuses on regulatory maturity, reimbursement readiness, and ecosystem development rather than segment-level revenue attribution.

Methodologically, the Cell & Gene Therapy Market evaluation integrates primary expert interviews, pipeline tracking, regulatory analysis, and secondary data from clinical trial databases, financial disclosures, and industry associations. Revenue forecasting incorporates product lifecycle assumptions, approval probabilities, and pricing evolution, while excluding granular segment-level revenue splits to maintain consistency and reliability.

Revenue & Spending Forecast: Cell And Gene Therapy Market

The global Cell & Gene Therapy Market is exhibiting a steep and sustained growth trajectory, driven by accelerating commercialization of advanced therapies, expanding clinical pipelines, and improving regulatory and reimbursement clarity. According to the revised forecast, global market revenue increased from USD 5.73 billion in 2022 to USD 9.98 billion in 2024, reflecting rapid early-stage adoption across oncology and rare genetic disorders.

During the forecast period, the cell and gene therapy (CGT) market is expected to scale sharply, reaching USD 51.37 billion by 2030, expanding at a robust compound annual growth rate (CAGR) of 31.4%. This growth curve highlights the transition of the CGT therapeutics market from pilot-scale commercialization toward broader clinical and geographic penetration.

Revenue acceleration is primarily supported by rising approvals of gene-modified cell therapies, increasing uptake of in vivo gene therapies, and growing confidence in outcomes-based reimbursement models. As therapies move from ultra-rare indications into larger patient populations, spending momentum across the Gene therapy market is expected to intensify.

Investment activity across manufacturing automation, viral vector capacity expansion, and digital quality systems is further reinforcing long-term revenue growth. Overall, the Cell And Gene Therapy Market is positioned to evolve into a core pillar of advanced therapeutics by the end of the forecast period, with revenue growth reflecting both clinical maturity and ecosystem scalability.

Market Segmentation Analysis: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is segmented based on therapeutic modality, therapeutic area, delivery approach, and geography, reflecting the multidimensional nature of the cell and gene therapy (CGT) market ecosystem.

By therapeutic modality, the CGT therapeutics market includes non-genetically modified cell therapies, gene-modified cell therapies, and gene therapies. Gene-modified cell therapies, particularly CAR-T and TCR-based platforms, currently represent the most commercially mature segment, supported by strong oncology uptake. Gene therapies delivered via viral and non-viral vectors are expanding rapidly as in vivo approaches gain regulatory and clinical validation.

Therapeutic area segmentation highlights oncology as the dominant focus within the Gene therapy market, accounting for the largest share of pipeline activity and commercial approvals. Hematologic malignancies remain central; however, solid tumors, neurological disorders, cardiovascular diseases, and inherited metabolic conditions are increasingly targeted. This diversification is broadening the addressable market for the Cell And Gene Therapy Market.

From a delivery perspective, ex vivo therapies continue to dominate approved products, but in vivo delivery is gaining momentum due to simplified logistics and scalability advantages. Hybrid in vivo-ex vivo platforms are emerging as innovation frontiers within the cell and gene therapy (CGT) market.

Geographically, North America leads in commercialization and reimbursement innovation, while Europe emphasizes structured access through managed entry agreements. Asia-Pacific is witnessing accelerated regulatory approvals and localized manufacturing investments. Overall, segmentation trends indicate a gradual shift toward scalable, platform-based solutions across the CGT therapeutics market.

Growth Drivers: Cell & Gene Therapy Market

The Cell & Gene Therapy Market is propelled by multiple structural growth drivers shaping the evolution of the cell and gene therapy (CGT) market.

First, rapid innovation in genome-editing tools, viral vectors, and delivery platforms is accelerating clinical success rates. These advancements are expanding the therapeutic reach of the Gene therapy market beyond rare diseases into more prevalent conditions.

Second, regulatory acceleration mechanisms such as RMAT, PRIME, and conditional approvals are significantly reducing development timelines. This regulatory support enhances capital efficiency and improves return on investment across the CGT therapeutics market.

Third, manufacturing transformation through automation and digitalization is addressing historical scalability constraints. Smart factories and AI-enabled process control are reducing variability and enabling consistent commercial output within the Cell And Gene Therapy Market.

Fourth, evolving reimbursement models-including outcomes-based agreements and installment payments-are mitigating payer resistance to high upfront costs. These frameworks are unlocking broader access and stabilizing long-term demand in the cell and gene therapy (CGT) market.

Finally, increasing venture funding and strategic partnerships are fueling pipeline expansion and ecosystem maturity, reinforcing sustained growth momentum across the CGT therapeutics market.

Growth Restraints: Cell & Gene Therapy Market

Despite strong momentum, the Cell & Gene Therapy Market faces several constraints that temper near-term growth in the cell and gene therapy (CGT) market.

High therapy prices remain a primary challenge, particularly for one-time curative treatments. Even with evolving reimbursement models, affordability concerns continue to limit adoption in cost-sensitive healthcare systems within the Gene therapy market.

Manufacturing complexity and capacity constraints also persist. While automation is improving scalability, technology transfer risks, workforce shortages, and quality control challenges still impact the CGT therapeutics market.

Regulatory heterogeneity across regions creates uncertainty for global commercialization. Differences in evidence requirements and long-term follow-up obligations slow market entry for the Cell And Gene Therapy Market in certain geographies.

Finally, long-term safety and durability concerns necessitate extended post-marketing surveillance, increasing development costs and payer scrutiny. Addressing these barriers is essential for sustaining long-term growth in the cell and gene therapy (CGT) market.

Competitive Landscape: Cell & Gene Therapy Market

The Cell & Gene Therapy Market features a dynamic and fragmented competitive environment comprising large pharmaceutical companies, specialized biotechnology firms, and CDMOs. Market leaders are leveraging platform-based strategies to scale across multiple indications within the CGT therapeutics market.

Major players focus on expanding portfolios through targeted acquisitions, licensing agreements, and strategic collaborations. M&A activity increasingly emphasizes next-generation delivery platforms, in vivo gene editing, and automated manufacturing capabilities, reflecting evolving priorities in the Gene therapy market.

Biotechnology firms continue to drive innovation, particularly in gene-modified cell therapies and novel vector technologies. Meanwhile, CDMOs are transitioning from service providers to integrated partners offering regulatory-ready capacity, digital manufacturing, and logistics support across the cell and gene therapy (CGT) market.

Competitive differentiation is increasingly defined by manufacturing readiness, regulatory execution, and payer engagement capabilities rather than clinical innovation alone. As competition intensifies, ecosystem collaboration will remain critical to sustaining leadership in the Cell and Gene Therapy Market.

Table of Contents

Research Scope

• Market Definition, Scope, and Segmentation
• Segmentation
• Definitions

Growth Environment: Transformation in the CGT Therapeutics Market

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative
• The Impact of the Top 3 Strategic Imperatives on the CGT Therapeutics Industry

Ecosystem in the CGT Therapeutics Market

• Key Highlights
• Pipeline Snapshot
• Pipeline Snapshot: Cell Therapy
• Pipeline Snapshot: Gene Therapy and Genetically Modified Cell Therapies
• Pipeline Snapshot: Gene-Modified Cell Therapy
• Clinical Trial Challenges and Strategies to Overcome
• Manufacturing Challenges and Strategies to Overcome
• Technology Trends Across the CGT Continuum
• Strategic Partnerships and Collaborations
• North America: CGT Regulatory & Reimbursement Models
• Europe: CGT Regulatory & Reimbursement Models
• Asia-Pacific: CGT Regulatory & Reimbursement Models
• LATAM and Middle East: CGT Regulatory & Reimbursement Models
• M&A Assessment
• Venture Financing Assessment
• Competitive Environment
• Key Competitors

Growth Generator in CGT Therapeutics Market

• Growth Metrics
• Growth Drivers
• Growth Restraints
• Research Process and Methodology
• Forecast Considerations
• Revenue Forecast
• Revenue Forecast Analysis
• Revenue Forecast by Product
• Revenue Forecast Analysis
• Revenue Forecast by Therapeutic Area
• Revenue Forecast Analysis
• Revenue Forecast by Region
• Forecast Analysis by Region
• Revenue Share
• Revenue Share Analysis

Growth Generator: Cell Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Source
• Forecast Analysis

Growth Generator: Gene-Modified Cell Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Technology
• Forecast Analysis

Growth Generator: Gene Therapy

• Growth Metrics
• Revenue Forecast
• Revenue Forecast by Technology
• Forecast Analysis

Growth Opportunity Universe

• Growth Opportunity 1: Regulatory Advisory Services for Accelerated Approvals
• Growth Opportunity 2: AI-Driven Bioprocess Optimization
• Growth Opportunity 3: Create Integrated Vector and Plasmid Manufacturing Hubs
• Growth Opportunity 4: Modernize Cold Chain and 3PL Networks with Blockchain and IoT
• Abbreviations
• Benefits and Impacts of Growth Opportunities
• Next Steps
• List of Exhibits
• Legal Disclaimer